Checkpoint Kinase News Today

Sareum (LON:SAR – Get Rating)‘s stock had its “buy” rating restated by analysts at Peel Hunt in a report issued on Tuesday, MarketBeat.com reports. They presently have a GBX 304 ($3.78) price target on the stock. Peel Hunt’s target price suggests a potential upside of 133.85% from the stock’s previous close. Sareum Price Performance Shares […]

Sareum Holdings plc (LON:SAR – Get Rating) shares crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of GBX 111.19 ($1.37) and traded as high as GBX 124 ($1.53). Sareum shares last traded at GBX 117.50 ($1.45), with a volume of 23,004 shares changing […]

Sareum Holdings plc (LON:SAR – Get Rating) shares passed above its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of GBX 107.93 ($1.34) and traded as high as GBX 122.66 ($1.53). Sareum shares last traded at GBX 120.50 ($1.50), with a volume of 14,994 shares traded. […]

The FDA has granted fast track designations to ACR-368 monotherapy for the treatment of patients with platinum-resistant ovarian cancer and endometrial cancer who are positive for predicted sensitivity to the agent using Acrivon Therapeutics’ OncoSignature® test.

The submission to the European Medicines Agency is based on results from the Phase 3 MAGNITUDE study evaluating niraparib in combination with abiraterone acetate plus prednisonefor the treatment of

Researchers discover how a gene mutation in the cancerous tumor leads to cell cycle dysregulation and heightened sensitivity to a class of inhibitors